Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1067
- Registration Number
- NCT02068508
Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants
Phase 1
Completed
- Conditions
- Bioavailability
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 52
- Registration Number
- NCT02064907
A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
Phase 2
Completed
- Conditions
- Involutional Osteoporosis
- Interventions
- Drug: NE-58095 IR PlaceboDrug: NE-58095 IRDrug: NE-58095 DRDrug: NE-58095 DR Placebo
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 871
- Registration Number
- NCT02063854
Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3339
- Registration Number
- NCT02058992
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 494
- Registration Number
- NCT02049814
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Phase 2
Completed
- Conditions
- Healthy VolunteersNorovirus, Prevention
- Interventions
- Biological: Hepatitis A VaccineBiological: Norovirus Bivalent VLP Vaccine
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 420
- Registration Number
- NCT02038907
- Locations
- 🇧🇪
Universiteit Antwerpen, Edegem, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 292
- Registration Number
- NCT02039505
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 157
- Registration Number
- NCT02038920
Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)
Phase 3
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT02037477
Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 437
- Registration Number
- NCT02024945
© Copyright 2025. All Rights Reserved by MedPath